French drug company Sanofi (NASDAQ: SNY) announced last week that they were planning to sell half of their 23.2 million share position in Regeneron Pharmaceuticals, Inc (NASDAQ: REGN). The investment has spanned 16 years and a number of collaborations between the companies. Some of the FDA-approved therapies are Kevzara, Praluent and Dupixent. While the plan […]

The post ‘Long Shot’ COVID-19 Treatment Looks Less Likely Following 10% Owner Selling appeared first on Trading Tips.